What's new in i.v. immunoglobulin therapy and pemphigus: High-dose i.v. immunoglobulin therapy and its mode of action for treatment of pemphigus

Journal of Dermatology

Volumn 37, Issue 3, 2010, Pages 239-245

  Aoyama, Yumi ^a,b  

^a OKAYAMA UNIVERSITY   (Japan)

^b OKAYAMA ROSAI HOSPITAL   (Japan)

Author keywords

Desmoglein autoimmune bullous disease; Immunoglobulin; Pemphigus

Indexed keywords

CORTICOSTEROID DERIVATIVE; FC RECEPTOR; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; PLACEBO;

ADJUVANT THERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; HUMAN; NONHUMAN; PEMPHIGUS; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ADRENAL CORTEX HORMONES; ADULT; AUTOANTIBODIES; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULIN G; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSIVE AGENTS; INFANT, NEWBORN; MULTICENTER STUDIES AS TOPIC; PEMPHIGUS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 77649230677     PISSN: 03852407     EISSN: 13468138     Source Type: Journal    
DOI: 10.1111/j.1346-8138.2009.00796.x     Document Type: Review

References (37)

1. Prins C, Gelfand EW, French LE. Intravenous immunoglobulin: properties, mode of action and practical use in dermatology. Acta Derm Venereol 2007 87 : 206 218.
2. Bystryn JC, Rudolph JL. IVIg treatment of pemphigus: how it works and how to use it. J Invest Dermatol 2005 125 : 1093 1098.
3. Aoyama Y, Nagasawa C, Nagai M, Kitajima Y. Severe pemphigus vulgaris: successful combination therapy of plasmapheresis followed by intravenous high-dose immunoglobulin to prevent rebound increase in pathogenic IgG. Eur J Dermatol 2008 18 : 557 560.
4. Sami N, Qureshi A, Ruocco E, Ahmed AR. Corticosteroid-sparing effect of intravenous immunoglobulin therapy in patients with pemphigus vulgaris. Arch Dermatol 2002 138 : 1158 1162. (Pubitemid 35025687)
5. Ishii N, Hashimoto T, Zillikens D, Ludwig RJ. High-Dose Intravenous Immunoglobulin (IVIG) Therapy in Autoimmune Skin Blistering Diseases. Clin Rev Allergy Immunol 2009. Published online: 27 June 2009; doi:.
6. Akerman L, Mimouni D, David M. Intravenous immunoglobulin for treatment of pemphigus. Clin Rev Allergy Immunol 2005 29 : 289 294.
7. Baum S, Scope A, Barzilai A, Azizi E, Trau H. The role of IVIG treatment in severe pemphigus vulgaris. J Eur Acad Dermatol Venereol 2006 20 : 548 552.
8. Arredondo J, Chernyavsky AI, Karaouni A, Grando SA. Novel mechanisms of target cell death and survival and of therapeutic action of IVIG in Pemphigus. Am J Pathol 2005 167 : 1531 1544.
9. Amagai M, Ikeda S, Shimizu H et al. A randomized double-blind trial of intravenous immunoglobulin for pemphigus. J Am Acad Dermatol 2009 60 : 595 603.
10. Ahmed AR, Spigelman Z, Cavacini LA, Posner MR. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med 2006 355 : 1772 1779. (Pubitemid 44631360)
11. Bystryn JC, Jiao D, Natow S. Treatment of pemphigus with intravenous immunoglobulin. J Am Acad Dermatol 2002 47 : 358 363.
12. Wetter DA, Davis MD, Yiannias JA et al. Effectiveness of intravenous immunoglobulin therapy for skin disease other than toxic epidermal necrolysis: a retrospective review of Mayo Clinic experience. Mayo Clin Proc 2005 80 : 41 47.
13. Ahmed AR. Intravenous immunoglobulin therapy in the treatment of patients with pemphigus vulgaris unresponsive to conventional immunosuppressive treatment. J Am Acad Dermatol 2001 45 : 679 690.
14. Crow AR, Song S, Semple JW, Freedman J, Lazarus AH. IVIG inhibits reticuloendothelial system function and ameliorates murine passive-immune thrombocytopenia independent of anti-idiotype reactivity. Br J Haematol 2001 115 : 679 686.
15. Viard I, Wehrli P, Bullani R et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998 282 : 490 493.
16. Mouthon L, Kaveri SV, Spalter SH et al. Mechanisms of action of intravenous immune globulin in immune-mediated diseases. Clin Exp Immunol 1996 104 (Suppl 1 3 9.
17. Soubrane C, Tourani JM, Andrieu JM et al. Biologic response to anti-CD16 monoclonal antibody therapy in a human immunodeficiency virus-related immune thrombocytopenic purpura patient. Blood 1993 81 : 15 19.
18. Ballow M. Mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory diseases. J Allergy Clin Immunol 1997 100 : 151 157.
19. Debre M, Bonnet MC, Fridman WH et al. Infusion of Fc gamma fragments for treatment of children with acute immune thrombocytopenic purpura. Lancet 1993 342 : 945 949.
20. Clarkson SB, Bussel JB, Kimberly RP, Valinsky JE, Nachman RL, Unkeless JC. Treatment of refractory immune thrombocytopenic purpura with an anti-Fc gamma-receptor antibody. N Engl J Med 1986 314 : 1236 1239.
21. Czernik A, Beutner EH, Bystryn JC. Intravenous immunoglobulin selectively decreases circulating autoantibodies in pemphigus. J Am Acad Dermatol 2008 58 : 796 801.
22. Green MG, Bystryn JC. Effect of intravenous immunoglobulin therapy on serum levels of IgG1 and IgG4 antidesmoglein 1 and antidesmoglein 3 antibodies in pemphigus vulgaris. Arch Dermatol 2008 144 : 1621 1624.
23. Li N, Zhao M, Hilario-Vargas J et al. Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases. J Clin Invest 2005 115 : 3440 3450.
24. Roopenian DC, Christianson GJ, Sproule TJ et al. The MHC class I-like IgG receptor controls perinatal IgG transport, IgG homeostasis, and fate of IgG-Fc-coupled drugs. J Immunol 2003 170 : 3528 3533.
25. Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 2007 7 : 715 725.
26. Chaudhury C, Mehnaz S, Robinson JM et al. The major histocompatibility complex-related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan. J Exp Med 2003 197 : 315 322.
27. Waldmann TA, Strober W. Metabolism of immunoglobulins. Prog Allergy 1969 13 : 1 110.
28. Rodewald R. pH-dependent binding of immunoglobulins to intestinal cells of the neonatal rat. J Cell Biol 1976 71 : 666 669.
29. Jones EA, Waldmann TA. The mechanism of intestinal uptake and transcellular transport of IgG in the neonatal rat. J Clin Invest 1972 51 : 2916 2927.
30. Simister NE, Rees AR. Isolation and characterization of an Fc receptor from neonatal rat small intestine. Eur J Immunol 1985 15 : 733 738.
31. Ghetie V, Hubbard JG, Kim JK, Tsen MF, Lee Y, Ward ES. Abnormally short serum half-lives of IgG in beta 2-microglobulin-deficient mice. Eur J Immunol 1996 26 : 690 696.
32. Antohe F, Radulescu L, Gafencu A, Ghetie V, Simionescu M. Expression of functionally active FcRn and the differentiated bidirectional transport of IgG in human placental endothelial cells. Hum Immunol 2001 62 : 93 105.
33. Ober RJ, Martinez C, Vaccaro C, Zhou J, Ward ES. Visualizing the site and dynamics of IgG salvage by the MHC class I-related receptor, FcRn. J Immunol 2004 172 : 2021 2029.
34. Ober RJ, Martinez C, Lai X, Zhou J, Ward ES. Exocytosis of IgG as mediated by the receptor, FcRn: an analysis at the single-molecule level. Proc Natl Acad Sci USA 2004 101 : 11076 11081.
35. Braun-Moscovici Y, Furst DE. Immunoglobulin for rheumatic diseases in the twenty-first century: take it or leave it? Curr Opin Rheumatol 2003 15 : 237 245. (Pubitemid 36532603)
36. Aoyama Y, Asai K, Hioki K, Funato M, Kondo N, Kitajima Y. Herpes gestationis in a mother and newborn: immunoclinical perspectives based on a weekly follow-up of the enzyme-linked immunosorbent assay index of a bullous pemphigoid antigen noncollagenous domain. Arch Dermatol 2007 143 : 1168 1172.
37. Arnold DF, Burton J, Shine B, Wojnarowska F, Misbah SA. An 'n-of-1' placebo-controlled crossover trial of intravenous immunoglobulin as adjuvant therapy in refractory pemphigus vulgaris. Br J Dermatol 2009 160 : 1098 1102.